Home/Filings/4/0000899243-20-019869
4//SEC Filing

Kakkar Rahul 4

Accession 0000899243-20-019869

CIK 0001807901other

Filed

Jul 20, 8:00 PM ET

Accepted

Jul 21, 7:35 PM ET

Size

17.1 KB

Accession

0000899243-20-019869

Insider Transaction Report

Form 4
Period: 2020-07-17
Kakkar Rahul
DirectorChief Executive Officer
Transactions
  • Award

    Stock Option (right to buy)

    2020-07-17+100,493100,493 total
    Exercise: $18.00Exp: 2030-07-16Common Stock (100,493 underlying)
  • Award

    Stock Option (right to buy)

    2020-07-17+27,18127,181 total
    Exercise: $18.00Exp: 2030-07-16Common Stock (27,181 underlying)
  • Conversion

    Common Stock

    2020-07-21+21,133702,515 total(indirect: By LLC)
  • Award

    Stock Option (right to buy)

    2020-07-17+221,067221,067 total
    Exercise: $18.00Exp: 2030-07-16Common Stock (221,067 underlying)
  • Purchase

    Common Stock

    2020-07-21$18.00/sh+14,000$252,00014,000 total
  • Conversion

    Series B Preferred Stock

    2020-07-21107,7680 total(indirect: By LLC)
    Common Stock (21,133 underlying)
Footnotes (5)
  • [F1]The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  • [F2]Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.
  • [F3]This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on August 5, 2020, with the remainder of the shares vesting in equal monthly installments following August 5, 2020 through August 5, 2023, subject to the reporting person's continued service on each applicable vesting date.
  • [F4]This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date.
  • [F5]This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on June 25, 2021, with the remainder of the shares vesting in equal monthly installments following June 25, 2021 through June 25, 2024, subject to the reporting person's continued service on each applicable vesting date.

Issuer

Pandion Therapeutics, Inc.

CIK 0001807901

Entity typeother

Related Parties

1
  • filerCIK 0001817416

Filing Metadata

Form type
4
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 7:35 PM ET
Size
17.1 KB